Eli Lilly (LLY) Return on Capital Employed (2009 - 2026)
Eli Lilly posted quarterly Return on Capital Employed of 42.94% for Q1 2026, up 806.0% year-on-year from 4.74% in Q1 2025, and up 15.35% on a QoQ basis from 37.22% in Q4 2025.
Eli Lilly (LLY) has 18 years of Return on Capital Employed data on file, last reported at 42.94% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed rose 806.0% year-over-year to 42.94%; the trailing twelve-month figure through Mar 2026 stood at 42.94% (up 806.0% YoY), and the FY2025 full-year result was 48.39%, up 1075.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 42.94%, up from 37.22% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 42.94% in Q1 2026 and bottomed at 20.0% in Q1 2023.
- The 5-year median for Return on Capital Employed is 28.23% (2024), against an average of 30.19%.
- The widest annual swing landed in 2023, when Return on Capital Employed tumbled 575 bps; it then soared 1002 bps in 2025.
- A 5-year view of Return on Capital Employed shows it stood at 25.64% in 2022, then advanced by 19 bps to 30.47% in 2023, then grew by 9 bps to 33.16% in 2024, then advanced by 12 bps to 37.22% in 2025, then grew by 15 bps to 42.94% in 2026.
- The last three Return on Capital Employed figures came in at 42.94% (Q1 2026), 37.22% (Q4 2025), and 37.83% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 42.94% |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 28.18% |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 16.47% |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | -5.22% |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 15.87% |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 21.53% |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | -10.20% |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | -6.84% |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 42.94% |
| Dec 31, 2025 | 37.22% |
| Sep 30, 2025 | 37.83% |
| Jun 30, 2025 | 39.15% |
| Mar 31, 2025 | 34.87% |
| Dec 31, 2024 | 33.16% |
| Sep 30, 2024 | 28.23% |
| Jun 30, 2024 | 31.69% |
| Mar 31, 2024 | 24.85% |
| Dec 31, 2023 | 30.47% |
| Sep 30, 2023 | 27.13% |
| Jun 30, 2023 | 21.77% |
| Mar 31, 2023 | 20.00% |
| Dec 31, 2022 | 25.64% |
| Sep 30, 2022 | 26.30% |
| Jun 30, 2022 | 27.52% |
| Mar 31, 2022 | 24.45% |
| Dec 31, 2021 | 21.91% |
| Sep 30, 2021 | 21.68% |
| Jun 30, 2021 | 20.66% |
| Mar 31, 2021 | 18.99% |
| Dec 31, 2020 | 20.81% |
| Sep 30, 2020 | 19.08% |
| Jun 30, 2020 | 20.79% |
| Mar 31, 2020 | 22.57% |
| Dec 31, 2019 | 21.59% |
| Sep 30, 2019 | 20.62% |
| Jun 30, 2019 | 21.02% |
| Mar 31, 2019 | 18.97% |
| Dec 31, 2018 | 17.87% |
| Sep 30, 2018 | 17.11% |
| Jun 30, 2018 | 17.58% |
| Mar 31, 2018 | 15.04% |
| Dec 31, 2017 | 15.90% |
| Sep 30, 2017 | 15.39% |
| Jun 30, 2017 | 15.53% |
| Mar 31, 2017 | 14.69% |
| Dec 31, 2016 | 14.23% |
| Sep 30, 2016 | 12.38% |
| Jun 30, 2016 | 13.16% |
| Mar 31, 2016 | 12.77% |
| Dec 31, 2015 | 12.96% |
| Sep 30, 2015 | 13.39% |
| Jun 30, 2015 | 12.39% |
| Mar 31, 2015 | 12.13% |
| Dec 31, 2014 | 12.93% |
| Sep 30, 2014 | 12.62% |
| Jun 30, 2014 | 15.62% |
| Mar 31, 2014 | 17.52% |
| Dec 31, 2013 | 21.60% |
| Sep 30, 2013 | 22.82% |
| Jun 30, 2013 | 22.25% |
| Mar 31, 2013 | 19.62% |
| Dec 31, 2012 | 19.31% |
| Sep 30, 2012 | 18.45% |
| Jun 30, 2012 | 20.70% |
| Mar 31, 2012 | 21.40% |
| Dec 31, 2011 | 24.23% |
| Sep 30, 2011 | 25.50% |
| Jun 30, 2011 | 26.40% |
| Mar 31, 2011 | 26.34% |
| Dec 31, 2010 | 26.58% |
| Sep 30, 2010 | 26.85% |
| Jun 30, 2010 | 26.18% |
| Mar 31, 2010 | 25.06% |
| Dec 31, 2009 | 33.12% |